Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „umeclidinium“
Suchtreffer
Begriffe & Kennungen
Anoro Ellipta (previously Anoro) · 4.5 · Although no formal in vivo drug interaction studies have been performed, inhaled umeclidinium/vilanterol has b
Eintrag öffnenAnoro Ellipta (previously Anoro) · 4.5 · Both umeclidinium and vilanterol are substrates of the P-glycoprotein transporter (P-gp). The effect of the mo
Eintrag öffnenAnoro Ellipta (previously Anoro) · 4.5 · Clinically significant interactions mediated by umeclidinium/vilanterol at clinical doses are considered unlik
Eintrag öffnenAnoro Ellipta (previously Anoro) · 4.5 · Co-administration of umeclidinium/vilanterol with other long-acting muscarinic antagonists, long-acting beta2-
Eintrag öffnenAnoro Ellipta (previously Anoro) · 4.5 · Umeclidinium is a substrate of cytochrome P450 2D6 (CYP2D6). The steady-state pharmacokinetics of umeclidinium
Eintrag öffnenAnoro Ellipta (previously Anoro) · 4.8 · The safety profile of ANORO ELLIPTA is based on safety experience with umeclidinium/vilanterol and the individ
Eintrag öffnenElebrato Ellipta · 4.5 · Clinically significant drug interactions mediated by fluticasone furoate/umeclidinium/vilanterol at clinical d
Eintrag öffnenElebrato Ellipta · 4.5 · Fluticasone furoate, umeclidinium and vilanterol are substrates of the P-glycoprotein transporter (P-gp). The
Eintrag öffnenElebrato Ellipta · 4.5 · Umeclidinium is a substrate of cytochrome P450 2D6 (CYP2D6). The steady-state pharmacokinetics of umeclidinium
Eintrag öffnenIncruse Ellipta (previously Incruse) · 4.5 · Although no formal in vivo interaction studies have been performed, inhaled umeclidinium has been used concomi
Eintrag öffnenIncruse Ellipta (previously Incruse) · 4.5 · Clinically significant interactions mediated by umeclidinium at clinical doses are considered unlikely due to
Eintrag öffnenIncruse Ellipta (previously Incruse) · 4.5 · Co-administration of umeclidinium with other long acting muscarinic antagonists or medicinal products containi
Eintrag öffnenIncruse Ellipta (previously Incruse) · 4.5 · Umeclidinium is a substrate of P-glycoprotein (P-gp) transporter. The effect of the moderate P- gp inhibitor v
Eintrag öffnenIncruse Ellipta (previously Incruse) · 4.5 · Umeclidinium is a substrate of cytochrome P450 2D6 (CYP2D6). The steady-state pharmacokinetics of umeclidinium
Eintrag öffnenIncruse Ellipta (previously Incruse) · 4.8 · The safety profile of umeclidinium was evaluated in patients with COPD who received doses of 55 micrograms or
Eintrag öffnenLaventair Ellipta (previously Laventair) · 4.5 · 5 umeclidinium or vilanterol Cmax. An approximately 1.4-fold increase in umeclidinium AUC was observed with no
Eintrag öffnenLaventair Ellipta (previously Laventair) · 4.5 · Although no formal in vivo drug interaction studies have been performed, inhaled umeclidinium/vilanterol has b
Eintrag öffnenLaventair Ellipta (previously Laventair) · 4.5 · Both umeclidinium and vilanterol are substrates of the P-glycoprotein transporter (P-gp). The effect of the mo
Eintrag öffnenLaventair Ellipta (previously Laventair) · 4.5 · Clinically significant interactions mediated by umeclidinium/vilanterol at clinical doses are considered unlik
Eintrag öffnenLaventair Ellipta (previously Laventair) · 4.5 · Co-administration of umeclidinium/vilanterol with other long-acting muscarinic antagonists, long-acting beta2-
Eintrag öffnen